(Total Views: 180)
Posted On: 12/05/2019 4:24:54 PM
Post# of 282
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Multiple Indications of Interest for Skyline Medical Division
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its receipt of interest from several parties for the possible acquisition of its Skyline Medical division, which produces and sells the STREAMWAY System for disposal of fluids in medical applications. Predictive Oncology previously announced intentions to focus its resources on its primary mission of applying artificial intelligence to precision medicine and drug discovery. “I am exceptionally pleased with the rapid growth and development of our Helomics and Tumor Genesis divisions, as well as the multiple indications of interest for our Skyline Medical division,” Predictive Oncology CEO Dr. Carl Schwartz said in the news release. “If this results in the sale of Skyline Medical, it would not only provide additional working capital, it would also allow Predictive Oncology to focus on the further development and commercialization of our two divisions focused on precision medicine.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its receipt of interest from several parties for the possible acquisition of its Skyline Medical division, which produces and sells the STREAMWAY System for disposal of fluids in medical applications. Predictive Oncology previously announced intentions to focus its resources on its primary mission of applying artificial intelligence to precision medicine and drug discovery. “I am exceptionally pleased with the rapid growth and development of our Helomics and Tumor Genesis divisions, as well as the multiple indications of interest for our Skyline Medical division,” Predictive Oncology CEO Dr. Carl Schwartz said in the news release. “If this results in the sale of Skyline Medical, it would not only provide additional working capital, it would also allow Predictive Oncology to focus on the further development and commercialization of our two divisions focused on precision medicine.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
